This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| MAPA | |
|---|---|
| Name | MAPA |
| Drug class | Research chemical; substituted amphetamine analog |
| Legal status | Variable by jurisdiction |
| Routes of administration | Oral, nasal insufflation, intravenous (reported) |
| Metabolism | Hepatic (reported) |
| Onset | Reported 20–90 minutes |
| Duration | Reported 4–12 hours |
MAPA
MAPA is a substituted amphetamine analog that has appeared in scientific literature, forensic reports, and recreational drug markets. It is discussed in the context of psychoactive phenethylamines alongside compounds monitored by institutions such as EMCDDA, UNODC, and national forensic laboratories like those of the FBI and NHS. MAPA has been characterized in analytical chemistry studies and case reports referenced by agencies including the Royal Society of Chemistry and university research groups.
The acronym MAPA derives from systematic nomenclature used for substituted amphetamines and is analogous to naming schemes seen in compounds like MDMA, MDA, DOB, 2C-B and Benzedrine. In literature, structural descriptors follow conventions established by the IUPAC and chemical registries such as CAS Registry Number assignments used in publications from entities like American Chemical Society and Wiley-VCH. Historical naming parallels include emergent labels used for novel psychoactive substances reported by Europol, National Institute on Drug Abuse, and research groups at institutions such as Johns Hopkins University and Imperial College London.
MAPA’s appearance in the public record coincides with waves of novel psychoactive substances discussed by organizations like EMCDDA and law enforcement agencies such as the DEA and West Midlands Police. Early analytical identifications were published by forensic chemistry teams affiliated with universities including University of Cambridge and University of Oxford, and in toxicology reports catalogued by the European Monitoring Centre for Drugs and Drug Addiction. Its distribution pathways reflected trends observed in markets studied by Silk Road-era researchers and darknet analyses reported by groups such as RAND Corporation and RAND Europe. Interest from academic medicinal chemistry labs at institutions like MIT, Stanford University, and University of California, San Francisco contributed to in vitro receptor profiling and metabolism studies.
Chemically, MAPA belongs to the class of substituted amphetamines related to families of compounds investigated in pharmacology by teams at National Institutes of Health, Scripps Research, and Roche. Structural analogs studied alongside MAPA include amphetamine, methamphetamine, MDMA, MDAI and PMA. Pharmacological characterization has involved assays used by researchers at Eli Lilly and Company, Pfizer, and academic groups in receptor binding studies targeting 5-HT2A receptor, DAT (dopamine transporter), SERT (serotonin transporter), and NET (norepinephrine transporter). Reported effects parallel those reported historically for substituted amphetamines in clinical accounts from NIDA-funded trials and case reports in journals cited by Lancet and BMJ.
Synthetic routes discussed in forensic and academic sources reference methods common to substituted amphetamines taught in organic chemistry courses at Massachusetts Institute of Technology, ETH Zurich, and University of Tokyo. Precursors and reagents noted in analytical seizure reports often resemble those catalogued by customs agencies like US Customs and Border Protection and the UK Border Force, with reference to synthetic steps comparable to those in historical syntheses by chemists such as Alexander Shulgin (noting analogy, not attribution). Laboratory analyses by forensic centers at Royal Canadian Mounted Police and Australian Federal Police describe chromatographic and spectrometric techniques, including GC-MS, LC-MS, and NMR spectroscopy used to confirm structure.
Regulatory treatment of MAPA varies among jurisdictions and is tracked by international bodies such as EMCDDA, UNODC, and national agencies including the DEA, ACMD (Advisory Council on the Misuse of Drugs), and the Home Office (United Kingdom). Some countries have controlled many substituted amphetamines under analogue, generic, or scheduling laws comparable to statutes like the Controlled Substances Act (United States) and the Misuse of Drugs Act 1971 (United Kingdom). Policy analyses by think tanks such as Brookings Institution and legal reviews in journals published by Oxford University Press discuss challenges in prosecuting and regulating emergent compounds.
Clinical and forensic toxicology literature reports sympathomimetic effects and risks analogous to those described for amphetamine and MDMA intoxication in case series from emergency departments affiliated with hospitals like Mayo Clinic and Cleveland Clinic. Toxicokinetic and toxicodynamic studies referenced by laboratories at Karolinska Institute and University of Barcelona indicate hepatic metabolism and potential interactions with medications metabolized by cytochrome P450 isoforms studied at NIH Clinical Center. Poison control centers such as those in Poison Control (United States) and corresponding agencies in Australia and Canada have issued advisories when novel amphetamine analogs appeared in local markets.
Reports of recreational use surface in ethnographic and sociological research by scholars at University of Manchester, University of California, Berkeley, and Goldsmiths, University of London, and in user forums monitored by research projects at RAND Corporation and University of Glasgow. Patterns of use mirror those documented in studies of nightlife and festival cultures involving Ibiza-scene analyses, Burning Man research, and surveys conducted by Global Drug Survey and EMCDDA. Discourses around harm reduction reference peer-led organizations such as DanceSafe and Release (charity), and public health responses draw on materials from WHO and Public Health England.
Category:Substituted amphetamines